Traws Pharma, Inc. Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31)
Traws Pharma, Inc. (TRAW) reported Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) of 2.04% for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsRiskFreeInterestRate · last filed 2017-11-09
- Traws Pharma, Inc. fair value assumptions, risk free interest rate (deprecated 2018-01-31) for the quarter ending 2017-03-31 was 1.72%, a 24.64% increase year-over-year.
- Traws Pharma, Inc. fair value assumptions, risk free interest rate (deprecated 2018-01-31) for the quarter ending 2016-03-31 was 1.38%.
- Traws Pharma, Inc. fair value assumptions, risk free interest rate (deprecated 2018-01-31) for fiscal 2016 was 1.93%.
| Period end | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 3 month | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 6 month | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 9 month | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-09-30 | 2.04% 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | 1.63% 10-Q · filed 2017-08-14 | |||
| 2017-03-31 | 1.72% 10-Q · filed 2017-05-15 | |||
| 2016-12-31 | 1.93% 10-K · filed 2017-03-29 | |||
| 2016-09-30 | 1.09% 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | 1.17% 10-Q · filed 2016-08-15 | |||
| 2016-03-31 | 1.38% 10-Q · filed 2016-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |